A4 – Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease
Thank you for your interest in the A4 Alzheimer"s Disease Study. The A4 study is investigating a new drug intervention that may reduce the impact of a protein known as "amyloid" or "beta amyloid" plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss.
The A4 anti-amyloid investigational drug targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD. By completing the following questions you are giving permission for the research team to contact you; however you are not committing yourself to taking part in the research study at this stage.
If you are a health professional wanting further information, please provide details in the comments section below.